Abstract:Bacterial toxins represent a vast reservoir of biochemical diversity that can be repurposed for biomedical applications. Such proteins include a group of predicted interbacterial toxins of the deaminase superfamily, members of which have found application in gene-editing techniques1,2. Because previously described cytidine deaminases operate on single-stranded nucleic acids3, their use in base editing requires the unwinding of double-stranded DNA (dsDNA)—for example by a CRISPR–Cas9 system. Base editing within mitochondrial DNA (mtDNA), however, has thus far been hindered by challenges associated with the delivery of guide RNA into the mitochondria4. As a consequence, manipulation of mtDNA to date has been limited to the targeted destruction of the mitochondrial genome by designer nucleases9,10.Here we describe an interbacterial toxin, which we name DddA, that catalyses the deamination of cytidines within dsDNA. We engineered split-DddA halves that are non-toxic and inactive until brought together on target DNA by adjacently bound programmable DNA-binding proteins. Fusions of the split-DddA halves, transcription activator-like effector array proteins, and a uracil glycosylase inhibitor resulted in RNA-free DddA-derived cytosine base editors (DdCBEs) that catalyse C•G-to-T•A conversions in human mtDNA with high target specificity and product purity. We used DdCBEs to model a disease-associated mtDNA mutation in human cells, resulting in changes in respiration rates and oxidative phosphorylation. CRISPR-free DdCBEs enable the precise manipulation of mtDNA, rather than the elimination of mtDNA copies that results from its cleavage by targeted nucleases, with broad implications for the study and potential treatment of mitochondrial disorders. An interbacterial toxin that catalyses the deamination of cytidines within double-stranded DNA forms part of a CRISPR-free, RNA-free base editing system that enables manipulation of human mitochondrial DNA.

CRISPR-free, strand-selective mitochondrial DNA base editing using a nickase

Strand-selective base editing of human mitochondrial DNA using mitoBEs

Streamlined process for effective and strand-selective mitochondrial base editing using mitoBEs

Research Progress in Mitochondrial Gene Editing Technology.

Strand-preferred base editing of organellar and nuclear genomes using CyDENT

A DddA ortholog-based and transactivator-assisted nuclear and mitochondrial cytosine base editors with expanded target compatibility

A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing

CRISPR-Cas12a System With Synergistic Phage Recombination Proteins for Multiplex Precision Editing in Human Cells

Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification.

CRISPR/Cas9-mediated base editors and their prospects for mitochondrial genome engineering

Utilization of TALEN and CRISPR/Cas9 Technologies for Gene Targeting and Modification

Development and application of CRISPR/Cas9 technologies in genomic editing.

Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity

Engineered mitochondrial A-to-G editors with enhanced efficiency and targeting scope

Mitochondrial base editor induces substantial nuclear off-target mutations

Expanding the editable genome and CRISPR–Cas9 versatility using DNA cutting-free gene targeting based on in trans paired nicking

Eliminating Base-Editor-induced Genome-Wide and Transcriptome-Wide Off-Target Mutations

Nuclear and mitochondrial DNA editing in human cells with zinc finger deaminases

Multiplexed base editing through Cas12a variant-mediated cytosine and adenine base editors

Adapting CRISPR/Cas9 System for Targeting Mitochondrial Genome

DNA base editing in nuclear and organellar genomes